A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab
- Conditions
- Interventions
- First Posted Date
- 2013-11-05
- Last Posted Date
- 2022-10-12
- Lead Sponsor
- Ludwig Institute for Cancer Research
- Target Recruit Count
- 104
- Registration Number
- NCT01975831
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸University of Virginia Division of Hematology and Oncology, Charlottesville, Virginia, United States
Phase I Study of Intralesional Bacillus Calmette-Guerin (BCG) Followed by Ipilimumab in Advanced Metastatic Melanoma
- Conditions
- Interventions
- First Posted Date
- 2013-04-23
- Last Posted Date
- 2022-10-12
- Lead Sponsor
- Ludwig Institute for Cancer Research
- Target Recruit Count
- 5
- Registration Number
- NCT01838200
- Locations
- 🇦🇺
Austin Health, LICR Melbourne Austin Branch, Heidelberg, Victoria, Australia
NY-ESO-1 Vaccine in Combination With Ipilimumab in Patients With Unresectable or Metastatic Melanoma
- First Posted Date
- 2013-03-13
- Last Posted Date
- 2022-10-12
- Lead Sponsor
- Ludwig Institute for Cancer Research
- Target Recruit Count
- 8
- Registration Number
- NCT01810016
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸Mount Sinai Medical Center, New York, New York, United States
🇺🇸University of Virginia Cancer Center, Charlottesville, Virginia, United States
Study of the Combination of Anti-OX40 and Ipilimumab in Patients With Metastatic Melanoma
- First Posted Date
- 2012-09-21
- Last Posted Date
- 2014-04-01
- Lead Sponsor
- Ludwig Institute for Cancer Research
- Registration Number
- NCT01689870
Single Dose of Intravenous rhTNF-α and Liposomal Doxorubicin in Patients With Advanced Solid Tumors or Lymphomas
- Conditions
- Interventions
- First Posted Date
- 2011-12-12
- Last Posted Date
- 2015-06-16
- Lead Sponsor
- Ludwig Institute for Cancer Research
- Registration Number
- NCT01490047
- Locations
- 🇩🇪
Krankenhaus Nordwest, Frankfurt, Germany
MAGE-A3 Protein + AS15 as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation
- Conditions
- Interventions
- First Posted Date
- 2011-06-27
- Last Posted Date
- 2022-10-25
- Lead Sponsor
- Ludwig Institute for Cancer Research
- Target Recruit Count
- 13
- Registration Number
- NCT01380145
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸New York University School of Medicine, New York, New York, United States
Study of ADI-PEG 20 in Patients With Relapsed Sensitive or Refractory Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2010-12-24
- Last Posted Date
- 2022-10-25
- Lead Sponsor
- Ludwig Institute for Cancer Research
- Target Recruit Count
- 22
- Registration Number
- NCT01266018
- Locations
- 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
🇨🇳National Taiwan University Hospital, Taipei City, Taiwan
🇺🇸Memorial Sloan-Kettering Cancer Center, New York, New York, United States
A Phase I Imaging and Pharmacodynamic Trial of CS-1008 in Patients With Metastatic Colorectal Cancer
- First Posted Date
- 2010-10-14
- Last Posted Date
- 2022-10-28
- Lead Sponsor
- Ludwig Institute for Cancer Research
- Target Recruit Count
- 19
- Registration Number
- NCT01220999
- Locations
- 🇦🇺
Ludwig Institute Tumor Targeting Program, Austin Health, Melbourne, Victoria, Australia
Vaccine Therapy in Stage II, III, or IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers
- Conditions
- Interventions
- First Posted Date
- 2008-12-05
- Last Posted Date
- 2023-10-04
- Lead Sponsor
- Ludwig Institute for Cancer Research
- Target Recruit Count
- 13
- Registration Number
- NCT00803569
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
🇺🇸NYU Cancer Institute at New York University Medical Center, New York, New York, United States
Phase II Study of KW2871 Combined With High Dose Interferon-α2b in Patients With Metastatic Melanoma
- First Posted Date
- 2008-05-16
- Last Posted Date
- 2022-10-12
- Lead Sponsor
- Ludwig Institute for Cancer Research
- Target Recruit Count
- 36
- Registration Number
- NCT00679289
- Locations
- 🇺🇸
University of Chicago Hospital, Chicago, Illinois, United States
🇺🇸University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States